150 related articles for article (PubMed ID: 24875783)
21. Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method.
Van Meter EM; Garrett-Mayer E; Bandyopadhyay D
Clin Trials; 2012 Jun; 9(3):303-13. PubMed ID: 22547420
[TBL] [Abstract][Full Text] [Related]
22. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles.
Yin J; Qin R; Ezzalfani M; Sargent DJ; Mandrekar SJ
Stat Med; 2017 Jan; 36(1):67-80. PubMed ID: 27633877
[TBL] [Abstract][Full Text] [Related]
23. Bayesian hybrid dose-finding design in phase I oncology clinical trials.
Yuan Y; Yin G
Stat Med; 2011 Jul; 30(17):2098-108. PubMed ID: 21365672
[TBL] [Abstract][Full Text] [Related]
24. A trivariate continual reassessment method for phase I/II trials of toxicity, efficacy, and surrogate efficacy.
Zhong W; Koopmeiners JS; Carlin BP
Stat Med; 2012 Dec; 31(29):3885-95. PubMed ID: 22807126
[TBL] [Abstract][Full Text] [Related]
25. Rolling continual reassessment method with overdose control: An efficient and safe dose escalation design.
Zhu J; Sabanés Bové D; Liao Z; Beyer U; Yung G; Sarkar S
Contemp Clin Trials; 2021 Aug; 107():106436. PubMed ID: 34000410
[TBL] [Abstract][Full Text] [Related]
26. Improvements to the Escalation with Overdose Control design and a comparison with the restricted Continual Reassessment Method.
Ji L; Lewinger JP; Krailo M; Groshen S; Conti DV; Asgharzadeh S; Sposto R
Pharm Stat; 2019 Nov; 18(6):659-670. PubMed ID: 31237419
[TBL] [Abstract][Full Text] [Related]
27. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method.
Normolle D; Lawrence T
J Clin Oncol; 2006 Sep; 24(27):4426-33. PubMed ID: 16983110
[TBL] [Abstract][Full Text] [Related]
28. A comparison of phase I dose-finding designs in clinical trials with monotonicity assumption violation.
Abbas R; Rossoni C; Jaki T; Paoletti X; Mozgunov P
Clin Trials; 2020 Oct; 17(5):522-534. PubMed ID: 32631095
[TBL] [Abstract][Full Text] [Related]
29. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.
Yin J; Paoletti X; Sargent DJ; Mandrekar SJ
Clin Trials; 2017 Dec; 14(6):611-620. PubMed ID: 28764555
[TBL] [Abstract][Full Text] [Related]
30. Bayesian model averaging continual reassessment method for bivariate binary efficacy and toxicity outcomes in phase I oncology trials.
Asakawa T; Hirakawa A; Hamada C
J Biopharm Stat; 2014; 24(2):310-25. PubMed ID: 24605971
[TBL] [Abstract][Full Text] [Related]
31. DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses.
Ursino M; Biard L; Chevret S
Biom J; 2022 Dec; 64(8):1486-1497. PubMed ID: 34729815
[TBL] [Abstract][Full Text] [Related]
32. Using the time-to-event continual reassessment method in the presence of partial orders.
Wages NA; Conaway MR; O'Quigley J
Stat Med; 2013 Jan; 32(1):131-41. PubMed ID: 22806898
[TBL] [Abstract][Full Text] [Related]
33. Interplay of priors and skeletons in two-stage continual reassessment method.
Iasonos A; O'Quigley J
Stat Med; 2012 Dec; 31(30):4321-36. PubMed ID: 22893483
[TBL] [Abstract][Full Text] [Related]
34. Dose-escalation designs in oncology: ADEPT and the CRM.
Shu J; O'Quigley J
Stat Med; 2008 Nov; 27(26):5345-53; discussion 5354-5. PubMed ID: 18752259
[TBL] [Abstract][Full Text] [Related]
35. Quasi-partial order continual reassessment method: Applying toxicity scores to cancer dose-finding drug combination trials.
O'Connell NS; Wages NA; Garrett-Mayer E
Contemp Clin Trials; 2023 Feb; 125():107050. PubMed ID: 36529437
[TBL] [Abstract][Full Text] [Related]
36. Dose finding with continuous outcome in phase I oncology trials.
Wang Y; Ivanova A
Pharm Stat; 2015; 14(2):102-7. PubMed ID: 25408518
[TBL] [Abstract][Full Text] [Related]
37. Borrowing historical information to improve phase I clinical trials using meta-analytic-predictive priors.
Chen X; Zhang J; Jiang Q; Yan F
J Biopharm Stat; 2022 Jan; 32(1):34-52. PubMed ID: 35594366
[TBL] [Abstract][Full Text] [Related]
38. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West.
Morita S
Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239
[TBL] [Abstract][Full Text] [Related]
39. Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.
Chen Z; Cui Y; Owonikoko TK; Wang Z; Li Z; Luo R; Kutner M; Khuri FR; Kowalski J
Contemp Clin Trials; 2014 Mar; 37(2):322-32. PubMed ID: 24530487
[TBL] [Abstract][Full Text] [Related]
40. Bridging continual reassessment method for phase I clinical trials in different ethnic populations.
Liu S; Pan H; Xia J; Huang Q; Yuan Y
Stat Med; 2015 May; 34(10):1681-94. PubMed ID: 25626429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
